The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes

[1] Ashby J(1994)Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis Hum Exp Toxicol 13 S1-117

[2] Brady A(2008)Overexpression of human truncated peroxisome proliferator-activated receptor induces apoptosis in HL-1 cardiomyocytes Cardiovasc Res 79 458-463

[3] Elcombe CR(2001)Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin) Pharmacol Toxicol 89 133-139

[4] Elliott BM(2013)PPAR- as a Key Nutritional and Environmental Sensor for Metabolic Adaptation Adv Nutr Int Rev J 4 439-452

[5] Ishmael J(2013)Human parenchymal and non-parenchymal liver cell isolation, culture and characterization Hepatol Int 7 951-958

[6] Odum J(2005)Phosphorylation of PPARs: from molecular characterization to physiological relevance Biochimie 87 33-38

[7] Tugwood JD(2009)Differential Regulation of Peroxisome Proliferator-Activated Receptor (PPAR)-α1 and Truncated PPARα2 as an Adaptive Response to Fasting in the Control of Hepatic Peroxisomal Fatty Acid β-Oxidation in the Hibernating Mammal Endocrinology 150 1192-1201

[8] Kettle S(2008)PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr Top Med Chem 8 728-749

[9] Purchase IF(1999)A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity Mol Endocrinol 13 1535-1549

[10] Beaumont J(2001)Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β J Biol Chem 276 33471-33477

[1] Ashby J(1994)Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis Hum Exp Toxicol 13 S1-117

[2] Brady A(2008)Overexpression of human truncated peroxisome proliferator-activated receptor induces apoptosis in HL-1 cardiomyocytes Cardiovasc Res 79 458-463

[3] Elcombe CR(2001)Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin) Pharmacol Toxicol 89 133-139

[4] Elliott BM(2013)PPAR- as a Key Nutritional and Environmental Sensor for Metabolic Adaptation Adv Nutr Int Rev J 4 439-452

[5] Ishmael J(2013)Human parenchymal and non-parenchymal liver cell isolation, culture and characterization Hepatol Int 7 951-958

[6] Odum J(2005)Phosphorylation of PPARs: from molecular characterization to physiological relevance Biochimie 87 33-38

[7] Tugwood JD(2009)Differential Regulation of Peroxisome Proliferator-Activated Receptor (PPAR)-α1 and Truncated PPARα2 as an Adaptive Response to Fasting in the Control of Hepatic Peroxisomal Fatty Acid β-Oxidation in the Hibernating Mammal Endocrinology 150 1192-1201

[8] Kettle S(2008)PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr Top Med Chem 8 728-749

[9] Purchase IF(1999)A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity Mol Endocrinol 13 1535-1549

[10] Beaumont J(2001)Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β J Biol Chem 276 33471-33477